SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

RO0504985 is an inhibitor of CMGC kinase proteins and has anti-human cytomegalovirus activity.

Strang, BL (2017) RO0504985 is an inhibitor of CMGC kinase proteins and has anti-human cytomegalovirus activity. Antiviral Res, 144. pp. 21-26. ISSN 1872-9096 https://doi.org/10.1016/j.antiviral.2017.05.004
SGUL Authors: Strang, Blair Lewis

[img] Microsoft Word (.docx) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (162kB)
[img]
Preview
Image (TIFF) (Figure 1) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview
[img]
Preview
Image (TIFF) (Figure 2) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview
[img]
Preview
Image (TIFF) (Figure 3) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB) | Preview
[img]
Preview
Image (TIFF) (Supplementary Figure 1) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview
[img] Microsoft Word (.docx) (Supplemntary material) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (110kB)
[img] Other (Supplementary table) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (78kB)

Abstract

Public-private partnerships allow many previously unavailable compounds to be screened for antiviral activity. Here a screening method was used to identify an oxindole compound, RO0504985, from a Roche kinase inhibitor library that inhibited human cytomegalovirus (HCMV) protein production. RO0504985 was previously described as an inhibitor of cyclin-dependent kinase 2 (CDK2). However, using kinase selectivity assays it was found that RO0504985 was an inhibitor of several CMGC group kinase proteins, including CDK2. Using virus yield reduction assays it was observed that RO0504985 inhibited replication of different HCMV strains at low micromolar concentrations. Western blotting was used to investigate how RO0504985 inhibited HCMV replication. Treatment of HCMV infected cells with RO0504985 inhibited production of the immediate early viral IE2 proteins and the late viral protein pp28. Thus, RO0504985 inhibited HCMV replication by preventing production of specific HCMV proteins necessary for virus replication.

Item Type: Article
Additional Information: © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: CDK, CMGC, Cytomegalovirus, Human, Kinase, Screen, Virology, 1108 Medical Microbiology, 1115 Pharmacology And Pharmaceutical Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Antiviral Res
ISSN: 1872-9096
Language: eng
Dates:
DateEvent
8 May 2017Accepted
10 May 2017Published Online
August 2017Published
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
R01 AI019838National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
R01 AI026077National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
PubMed ID: 28501424
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/108889
Publisher's version: https://doi.org/10.1016/j.antiviral.2017.05.004

Actions (login required)

Edit Item Edit Item